OncoTherapy Science (FRA:30O) Beginning Cash Position: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:30O OncoTherapy Science Inc FRA:30O
52 GF Score
Price €0.08
GF Value €0.07
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science Beginning Cash Position?

OncoTherapy Science FRA:30O +7.01% 52 Beginning Cash Position is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:30O with a GF Score™ of 52/100 and a GF Value™ of €0.07. The stock has 1 warning sign investors should review.

OncoTherapy Science's Beginning Cash Position for the quarter that ended in Mar. 2026 was €0.00 Mil.

OncoTherapy Science's annual Beginning Cash Position declined from Mar. 2024 (€6.86 Mil) to Mar. 2025 (€3.28 Mil) but then increased from Mar. 2025 (€3.28 Mil) to Mar. 2026 (€4.55 Mil).

OncoTherapy Science Beginning Cash Position Related Terms

OncoTherapy Science Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science Beginning Cash Position Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.20 12.84 6.86 3.28 4.55

OncoTherapy Science Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:30O
52GF Score
OncoTherapy Science Inc FRA:30O
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €0.00 Mil mean?
OncoTherapy Science (FRA:30O) has a Beginning Cash Position of €0.00 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on OncoTherapy Science and its competitors.
Is OncoTherapy Science's Beginning Cash Position too high?
OncoTherapy Science's current Beginning Cash Position is €0.00 Mil. Overall, OncoTherapy Science has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Beginning Cash Position compare to VRTX and REGN?
OncoTherapy Science's Beginning Cash Position of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current Beginning Cash Position is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
OncoTherapy Science (FRA:30O) has a current Beginning Cash Position of €0.00 Mil. The stock's GF Value™ is €0.07, compared to a current price of €0.08 — trading 20% above its estimated fair value. The current Beginning Cash Position is €0.00 Mil. OncoTherapy Science's overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For OncoTherapy Science (FRA:30O), the current Beginning Cash Position is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoTherapy Science (FRA:30O) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of €0.08 is trading 20% above its estimated GF Value™ of €0.07.

Key valuation signals for FRA:30O:

  • Beginning Cash Position: €0.00 Mil
  • GF Value™: €0.07 vs. price of €0.08 (20% above fair value)
  • GF Score™: 52/100 with 1 warning sign

No single metric tells the full story. See the FRA:30O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoTherapy Science Business Description

Other Exchanges 4564:Japan
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
52GF Score

Get the complete analysis for FRA:30O

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.08
Price
€0.07
GF Value